627

Khan S[1], Panicker J[1], Gonzales G[1], Elneil S[1], Fowler C[1], Dasgupta P[2], Kessler T[3]
1. *National Hospital for Neurology & Neurosurgery London,* ***2.*** *Guys and St. Thomas' Hospitals NHS Foundation Trust London,* ***3.*** *National Hospital for Neurology & Neurosurgery London & University of Bern Switzerland*

COMPLETE CONTINENCE AFTER BOTULINUM NEUROTOXIN TYPE A INJECTIONS FOR REFRACTORY IDIOPATHIC DETRUSOR OVERACTIVITY INCONTINENCE: PATIENT REPORTED OUTCOME

Hypothesis / aims of study

To investigate the change in patient reported continence rate after intradetrusor injections of botulinum neurotoxin type A (BoNT/A) for treatment of refractory idiopathic detrusor overactivity (IDO) incontinence.

Study design, materials and methods

74 patients (51 women, 23 men) with refractory IDO incontinence treated for the first time with intradetrusor injections of 200 U BoNT/A were evaluated in this non-randomized, open-label, cohort study. Changes in patient-reported urinary frequency, urgency incontinence, and stress incontinence were assessed using the condition-specific validated short form of Urogenital Distress Inventory (UDI 6) before and 4 weeks after BoNT/A treatment.

Results & Interpretation of Results

The patient reported outcome of complete continence (defined as a score of 0 in both the urgency and stress incontinence subscales of the UDI 6) was 51% (38/74) four weeks after intradetrusor injections of BoNT/A. In patients who were not completely continent, median urgency incontinence scores reduced significantly from 100 to 0 ($p<0.001$), stress incontinence scores from 33 to 0 ($p<0.001$) and median urinary frequency scores from 100 to 33 ($p<0.001$), respectively.

Concluding message

An excellent response with more than 50% of patients reporting complete continence 4 weeks after BoNT/A treatment reveals the efficacy of this emerging treatment for patients with refractory IDO incontinence. Furthermore, in those in whom complete continence was not achieved there is a notable and significant reduction in reported urgency incontinence, stress incontinence and urinary frequency.

Figure 1.

Patient reported incontinence before and 4 weeks after intradetrusor BoNT/A using the subscales of the validated UDI 6 questionnaire in 74 patients



Specify source of funding or grant	**Self funded with permission of the Use of Medicines Committee of the UCL Hospitals NHS Foundation Trust**
Is this a clinical trial?	**No**
What were the subjects in the study?	**HUMAN**
Was this study approved by an ethics committee?	**Yes**
Specify Name of Ethics Committee	**Research Ethics Committee & Use of Medicines Committee of the UCL Hospitals NHS Foundation Trust London**
Was the Declaration of Helsinki followed?	**Yes**
Was informed consent obtained from the patients?	**Yes**